S&P Biotech ETF (CURE) – Global X ETFs Australia
Australia
Search

CURE

S&P Biotech ETF

Invest in CURE
Overview Performance Holdings & Characteristics Research Documents Announcements FAQs

Reasons to Consider CURE

High Growth Potential

Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.

Structural Tailwinds

The cost of genomic sequencing has dropped from nearly USD$100mm per genome in 2002 to less than USD$1,000 in 2020. Adoption has continued to rise, as costs plummet.1

Targeted Exposure

CURE provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

1 National Human Genome Research Institute, Nov 2021

Product Information As of 8 Dec 2023

Inception Date 8 Nov 2018
Management Costs (% p.a.) 0.45
Currency Hedged No
Domicile Australia
Legal Form Managed Investment Scheme
SMSF Eligible Yes

NAV Information As of 8 Dec 2023

NAV/Unit (A$) 41.18360000
Currency (NAV) AUD
Shares Outstanding 884,012
AUM (A$) 36,406,762.39

Product Summary

The Global X S&P Biotech ETF (CURE) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Product Objective

The Global X S&P Biotech ETF (CURE) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.

Trading Details

Ticker CURE
Bloomberg Code CURE AU Equity
ISIN AU0000028110
Trading Hours 10:00AM – 4:00PM

Management & Administration

Issuer Global X Management (AUS) Limited
Custodian The Hongkong and Shanghai Banking Corporation Limited, Sydney Branch
Registrar Computershare Investor Services Pty Limited

Benchmark Information

Benchmark S&P Biotechnology Select Industry Index
Provider S&P Indices
Ticker SPSIBIN

Distributions As of 31 Oct 2023

12-Month Yield 0.00%
12-Month Franking Level 0.00%
Distribution Frequency Annually
Distribution History View

Performance Table As of 8 Dec 2023

Total Return (Fund) Total Return (Benchmark) Tracking Difference Tracking Error
1 Month 11.25% 11.35% -0.10% 0.05%
3 Months -2.20% -2.02% -0.18% 0.14%
1 Year -0.20% 0.11% -0.32% 1.65%
3 Year p.a. -14.06% -13.78% -0.28% 0.98%
5 Year p.a. 1.85% 2.30% -0.45% 0.86%
10 Year p.a. -- -- -- --
Since Inception p.a. 0.57% 0.99% -0.42% 0.86%

Top Holdings As of 11 Dec 2023

Full Holdings (.xlsx)
Net Assets (%) Name SEDOL Market Price (Local) Shares Held Market Value (A$)
2.27 IMMUNOGEN INC 2457864 29.21 18,649 827,051
1.93 MIRATI THERAPEUT BBPK0J0 56.49 8,210 704,142
1.85 TG THERAPEUTICS B828K63 15.72 28,180 672,572
1.84 APELLIS PHARMACE BYTQ6X1 62.73 7,041 670,587
1.69 BLUEPRINT MEDICI BWY52P3 73.98 5,484 615,966
1.60 IMMUNOVANT INC BJRFSB7 39.19 9,761 580,784
1.58 CRISPR THERAPEUT BDHF4K6 64.54 5,863 574,505
1.55 BIOHAVEN LTD BPLZ7S5 33.06 11,274 565,882
1.44 IONIS PHARMACEUT BDJ0LS6 48.69 7,105 525,230
1.42 VIKING THERAPEUT BQQG1V1 18.48 18,426 516,985
1.40 BRIDGEBIO PHARMA BK1KWG8 32.52 10,306 508,846
1.36 KARUNA THERAPEUT BJMLSD2 205.48 1,589 495,723
1.31 IOVANCE BIOTHERA BF0DMK7 6.40 49,208 478,147
1.31 UNITED THERAPEUT 2430412 241.65 1,301 477,320
1.31 NEUROCRINE BIOSC 2623911 117.28 2,679 477,026
1.31 NATERA INC BYQRG48 58.15 5,402 476,924
1.31 SEAGEN INC BLPK4D2 218.98 1,432 476,094
1.29 MADRIGAL PHARMAC BD59BS7 208.32 1,489 470,946
1.27 VAXCYTE INC BKPVGH6 56.67 5,389 463,668
1.27 GILEAD SCIENCES 2369174 79.02 3,852 462,135
1.27 AMGEN INC 2023607 269.12 1,129 461,302
1.27 HALOZYME THERAPE 2975098 39.95 7,603 461,155
1.26 BIOMARIN PHARMAC 2437071 92.94 3,246 458,033
1.26 IRONWOOD PHARMAC B3MZ6K5 10.48 28,747 457,403
1.25 TWIST BIOSCIENCE BGKG6G7 26.98 11,147 456,610
1.25 VERTEX PHARM 2931034 350.15 853 453,470
1.23 REGENERON PHARM 2730190 840.14 352 448,993
1.23 BEAM THERAPEUTIC BK6L288 26.40 11,186 448,357
1.22 ARCELLX INC BPCJ1Q2 56.22 5,222 445,731
1.22 ABBVIE INC B92SR70 149.28 1,965 445,358
1.21 EXELIXIS INC 2576941 22.00 13,242 442,305
1.15 CYTOKINETICS INC BBBSBJ5 34.10 8,119 420,341
1.15 RECURSION PHAR-A BM9FJ13 7.60 36,326 419,157
1.13 SAGE THERAPEUTIC BP4GNK9 20.01 13,549 411,623
1.13 BIOGEN INC 2455965 239.29 1,130 410,533
1.13 CEREVEL THERAPEU BMVMJ12 41.22 6,546 409,665
1.09 ALKERMES PLC B3P6D26 25.86 10,149 398,471
1.09 AMICUS THERAPEUT B19FQ48 11.22 23,292 396,776
1.05 KRYSTAL BIOTECH BD6JX35 106.86 2,360 382,889
1.05 INSMED INC 2614487 27.96 8,995 381,842
1.04 INCYTE CORP 2471950 54.70 4,576 380,031
1.03 ALNYLAM PHARMACE B00FWN1 170.04 1,454 375,371
1.02 ULTRAGENYX PHARM BJ62Z18 40.46 6,021 369,862
1.01 EXACT SCIENCES 2719951 64.72 3,738 367,302
0.99 CATALYST PHARMAC B1G7Q03 14.15 16,789 360,684
0.98 PROTAGONIST THER BDCBCD8 20.36 11,519 356,072
0.98 ARROWHEAD PHARMA BYQBFJ8 23.95 9,792 356,059
0.97 ACADIA PHARMACEU 2713317 20.98 11,069 352,581
0.95 ROIVANT SCIENCES BMW4NZ9 9.83 23,237 346,800
0.94 INTELLIA THERAPE BYZM6C2 29.02 7,731 340,626
0.93 NUVALENT INC-A BMVBZD3 70.66 3,147 337,610
0.91 MODERNA INC BGSXTS3 80.32 2,720 331,694
0.90 CRINETICS PHARMA BDD19F8 33.27 6,502 328,432
0.89 SAREPTA THERAPEU B8DPDT7 87.03 2,442 322,671
0.87 DYNAVAX TECHNOLO BRJZSK0 13.31 15,677 316,801
0.84 ROCKET PHARMACEU BDFKQ07 25.23 7,947 304,415
0.81 RHYTHM PHARMACEU BF2YWG4 36.49 5,355 296,673
0.79 ARDELYX INC BN89V40 5.23 36,108 286,715
0.78 PROTHENA CORP PL B91XRN2 36.08 5,160 282,658
0.78 SPRINGWORKS THER BGMGM89 31.50 5,907 282,503
0.77 REVOLUTION MEDIC BL71K91 24.59 7,463 278,623
0.76 NOVAVAX INC BJDQXG4 5.57 32,641 276,035
0.75 PTC THERAPEUTICS B17VCN9 26.39 6,786 271,893
0.75 VERACYTE INC BFTWZY0 25.62 6,988 271,817
0.71 EDITAS MEDICINE BZ8FPH3 10.51 16,299 260,081
0.71 CELLDEX THERAPEU BJLV8T9 31.43 5,420 258,636
0.69 VIR BIOTECHNOLOG BK4PZ38 9.62 17,276 252,327
0.65 VIRIDIAN THERAPE BMDH2B6 18.14 8,627 237,598
0.65 SYNDAX PHARMACEU BN7Q7R7 16.65 9,344 236,207
0.63 ARCUS BIOSCIENCE BDZT9Y9 15.77 9,629 230,546
0.63 BIOCRYST PHARM 2100362 5.69 26,570 229,535
0.62 MIRUM PHARMACEUT BJDX8Y8 32.86 4,514 225,203
0.58 VERICEL CORP BSBMN89 33.86 4,119 211,750
0.58 DENALI THERAPEUT BD2B4V0 18.37 7,543 210,377
0.55 IDEAYA BIOSCIENC BK0VHF6 30.89 4,246 199,133
0.54 BIOMEA FUSION IN BNKF6N0 16.89 7,690 197,197
0.54 GERON CORP 2370381 2.07 62,563 196,623
0.53 MYRIAD GENETICS 2614153 18.52 6,857 192,806
0.53 DISC MEDICINE IN BMGJZJ8 61.01 2,076 192,298
0.52 MORPHIC HOLDING BK8M4J4 27.17 4,575 188,724
0.52 89BIO INC BK1K484 9.86 12,563 188,068
0.51 BLUEBIRD BIO INC BBFL7S1 2.86 42,886 186,220
0.50 AKERO THERAPEUTI BK7Y2V9 19.87 6,037 182,123
0.49 VERVE THERAPEUTI BNKGXX2 12.79 9,218 179,000
0.49 RELAY THERAPEUTI BN2R582 9.37 12,424 176,745
0.47 KYMERA THERAPEUT BMPRZV5 23.00 4,938 172,435
0.43 ARCTURUS THERAPE BKC9SX3 23.79 4,368 157,769
0.43 POINT BIOPHARMA BNKJ1S2 14.06 7,339 156,663
0.43 TRAVERE THERAPEU BLFGJD5 8.64 11,907 156,193
0.42 MANNKIND CORP BF081J4 3.58 28,144 152,973
0.41 CAREDX INC BP3YM74 9.81 10,041 149,552
0.40 CARIBOU BIOSCIEN BNYJR68 5.81 16,690 147,224
0.40 AGIOS PHARMACEUT BCBVTX1 22.05 4,395 147,134
0.40 DAY ONE BIOPHARM BLB0YH0 12.27 7,796 145,232
0.40 INHIBRX INC BK1MBC3 24.97 3,810 144,440
0.38 UNIQURE NV BJFSR88 7.17 12,854 139,830
0.36 ZENTALIS PHARMAC BMQ5T49 12.96 6,599 129,846
0.35 REGENXBIO INC BZ0G875 19.58 4,336 128,898
0.34 KURA ONCOLOGY IN BYZD465 10.81 7,638 125,358
0.34 AVIDITY BIOSCIEN BMWHPY1 7.54 10,862 124,344
0.33 KINIKSA PHARMA-A BD0MGM0 17.27 4,575 119,958
0.32 ADMA BIOLOGICS I B9NSBM2 3.71 20,572 115,877
0.31 XENCOR INC BGCYWN8 20.25 3,642 111,972
0.30 ANAVEX LIFE SCIE BYTYP72 7.96 8,905 107,620
0.28 KEROS THERAPEUTI BM7V485 35.65 1,912 103,489
0.28 DECIPHERA PHARMA BZ1LFB2 14.80 4,597 103,296
0.27 COHERUS BIOSCIEN BRK0149 2.22 28,820 97,139
0.27 ALLOGENE THERAPE BFZNYB7 2.47 25,820 96,827
0.26 CABALETTA BIO IN BK5MWR1 16.23 3,884 95,707
0.26 VERA THERAPEUTIC BL55460 13.70 4,487 93,330
0.25 4D MOLECULAR THE BKLXFX5 14.94 4,051 91,888
0.25 MIMEDX GROUP INC B1Z3TW5 8.01 7,386 89,823
0.24 RAPT THERAPEUTIC BK5T6R0 17.48 3,227 85,642
0.23 COGENT BIOSCIENC BLR6XK8 8.64 6,307 82,734
0.21 DYNE THERAPEUTIC BN15WD1 11.18 4,586 77,843
0.19 REPLIMUNE GROUP BDDVW37 7.29 6,145 68,013
0.19 SPDR S&P BIOTECH B0Y90K2 79.32 560 67,440
0.17 AGENUS INC B58J3K4 0.75 55,286 62,660
0.17 SANA BIOTECHNOLO BMFJJ97 3.72 10,685 60,348
0.16 ACELYRIN INC BQPF874 6.83 5,715 59,263
0.16 ALECTOR INC BJ4LDC4 6.12 6,139 57,042
0.15 PRIME MEDICINE I BPBJFM7 8.50 4,239 54,705
0.14 SERES THERAPEUTI BYNQNP8 1.09 30,796 50,964
0.14 ANAPTYSBIO INC BDRW1L7 16.36 2,050 50,919
0.12 ARCUTIS BIOTHERA BKX9VD3 2.16 13,789 45,220
0.12 AVID BIOSERVICES BFMZ4W7 4.64 6,375 44,910
0.12 NURIX THERAPEUTI BMVLGP2 8.60 3,250 42,435
0.12 ALDEYRA THERAPEU BLD36T3 3.16 8,838 42,402
0.11 ITEOS THERAPEUTI BMWXFT4 9.84 2,800 41,831
0.11 LYELL IMMUNOPHAR BN6MB18 1.92 13,977 40,744
0.10 SCILEX HOLDING C BLKFRT9 1.10 21,910 36,592
0.02 MURAL ONCOLOGY BRJQ8L4 3.99 1,014 6,143
Holdings are subject to change.

Sector Breakdown As of 11 Dec 2023

Sector Weight (%)
Health Care 99.7
None 0.2
Other/Cash 0.1

Country Breakdown As of 11 Dec 2023

Country Weight (%)
United States 96.0
Ireland 1.9
Switzerland 1.6
Netherlands 0.4
Other/Cash 0.1

Research

AI Applications in Healthcare: From Drug Discovery to Patient Care

Read More

Another Year of Blockbuster Drug and Treatment Approvals Possible in 2023

Read More

Liquid Biopsy: A Pathway to Earlier and Less Invasive Cancer Detection

Read More

Documents

FAQs

  • What is biotechnology?

    Biotechnology includes companies primarily engaged in the research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering. It includes companies specialising in protein-based therapeutics to treat human diseases. It excludes companies manufacturing products using biotechnology but without a healthcare application. Biotechnology is a sub-industry of the healthcare sector.

  • How does biotechnology differ from healthcare?

    Biotechnology is a sub-industry within the Healthcare sector.

    The Healthcare sector refers to all those industries involved in providing goods and services to manage the health needs of individuals and populations. There are two main groupings within the healthcare sector according to the Global Industry Classification Standards (GICS) including:

    Healthcare equipment and services

    Pharmaceuticals, biotechnology, and Life Sciences.

  • How are companies in CURE weighted?

    Companies in CURE are equally weighted (subject to liquidity constraints), meaning each holding makes up the same portion of the portfolio at each quarterly rebalance and therefore contributes equally to overall performance.

    The choice of an equal weighting scheme provides investors exposure to the overall sector and allows all stocks to contribute equally to returns. Large-cap stocks do not dominate as they do where holdings are weighted by market capitalisation.

  • Why use CURE for biotechnology exposure?

    While biotechnology can be a lucrative space, it can also be high risk. The drug development process is very lengthy with high failure rates and it is an area that is sensitive to government policy. Using an ETF like CURE not only spreads the risk over many biotechnology companies but reduces the single stock risk further by using an equal weight method.

    CURE enables investors to access the growth in the U.S. biotechnology sector, without having to pick individual winners.

  • How can you use CURE in a portfolio?

    CURE may be used as a tool for expressing long-term strategic or short-term tactical views on the biotechnology sub-industry.

    CURE can also aid portfolio diversification via investment in a sector that is underrepresented in the Australian market.

Investments may go up or down in value and you may lose some or all of the amount invested. Past performance is not necessarily a guide to future performance. Any advice provided by Global X Management (AUS) Limited (“Global X”) is general advice and does not take into account your personal objectives, financial situation or needs. You should consult an independent investment adviser prior to making an investment in order to determine its suitability to your circumstances. This material may contain links to third party websites. Global X does not control and is not responsible for the information contained within third party websites. None of these links imply Global X’s support, endorsement or recommendation of any other company, product or service.

Global X Management (AUS) Limited ACN 150 433 828 AFSL No 466778

Back to Top